Response to therapy is affected by the genetic heterogeneity of acute myeloid leukemia (AML) and persistence of leukemic cells below the threshold of morphological complete remission (mCR). Such persistence is called minimal (or measurable) residual disease (MRD). Areas covered: MRD assessment allows early identification of patients who are at high risk of relapse and who should timely receive aggressive therapy (e.g. allogeneic stem cell transplantation) and of those with a good quality mCR in whom an aggressive front-line therapy can be spared, avoiding the harm of excessive treatment toxicity. The most exploited methods to assess MRD are multiparameter flow cytometry (via identification of immunophenotypic aberrancies) or PCR-based assays (via identification of cytogenetic/molecular abnormalities). Expert commentary: A growing body of evidences demonstrates that positive MRD-testing at various time-points throughout the treatment course identifies patients at high risk of relapse. We will focus on the role of MRD as a biomarker to refine risk assessment and to prospectively direct treatment choices in adult with AML.

Buccisano, F., Maurillo, L., Del Principe, M.I., Di Veroli, A., De Bellis, E., Biagi, A., et al. (2018). Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. EXPERT REVIEW OF HEMATOLOGY, 11(4), 307-313 [10.1080/17474086.2018.1447378].

Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia

Buccisano F.;Del Principe M. I.;Di Veroli A.;Amadori S.;Voso M. T.;Lo-Coco F.;Arcese W.;Venditti A.
2018

Abstract

Response to therapy is affected by the genetic heterogeneity of acute myeloid leukemia (AML) and persistence of leukemic cells below the threshold of morphological complete remission (mCR). Such persistence is called minimal (or measurable) residual disease (MRD). Areas covered: MRD assessment allows early identification of patients who are at high risk of relapse and who should timely receive aggressive therapy (e.g. allogeneic stem cell transplantation) and of those with a good quality mCR in whom an aggressive front-line therapy can be spared, avoiding the harm of excessive treatment toxicity. The most exploited methods to assess MRD are multiparameter flow cytometry (via identification of immunophenotypic aberrancies) or PCR-based assays (via identification of cytogenetic/molecular abnormalities). Expert commentary: A growing body of evidences demonstrates that positive MRD-testing at various time-points throughout the treatment course identifies patients at high risk of relapse. We will focus on the role of MRD as a biomarker to refine risk assessment and to prospectively direct treatment choices in adult with AML.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - Malattie del Sangue
English
Con Impact Factor ISI
Acute myeloid leukemia; RT-qPCR; biomarkers; multiparametric flow-cytometry; prognosis; stem cell transplantation
Buccisano, F., Maurillo, L., Del Principe, M.I., Di Veroli, A., De Bellis, E., Biagi, A., et al. (2018). Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. EXPERT REVIEW OF HEMATOLOGY, 11(4), 307-313 [10.1080/17474086.2018.1447378].
Buccisano, F; Maurillo, L; Del Principe, Mi; Di Veroli, A; De Bellis, E; Biagi, A; Zizzari, A; Rossi, V; Rapisarda, V; Amadori, S; Voso, Mt; Lo-Coco, F; Arcese, W; Venditti, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
buccisano2018.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/198737
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact